One of the most significant hurdles most biotechnology companies have to overcome is FDA approval. To receive FDA approval, a process that can take up to two and a half years, the company must submit an application (usually about 100,000 pages) to the FDA. This extensive process has been a barrier to many new products that will never compete in the market.

Fortunately for Kraig Biocraft, their technology doesn’t have to be approved by the FDA, which makes it much easier for investors to monetize their investment since the costs are significantly reduced and the time to market is much shorter. The potential for success is also much greater as only 5 out of 5,000 compounds discovered in the pre-clinical stage ever make it through the entire FDA approval process.

Let us hear your thoughts: Kraig Biocraft Laboratories, Inc. Message Board

Last 5 posts by QualityStocks

• Omnicity Corp. (OMCY.OB) Announces Addition of New Board Member - November 20th, 2009
• Muscle Flex, Inc. (MFLI.PK) Announces Release Time for the BUDDY Tablet Caddy Two-Minute Commercial and Landing Page - November 20th, 2009
• Artfest International, Inc. (ARTS.OB) Announces Revenue Profit Jumps - November 20th, 2009
• Omnicity Corp.’s (OMCY.OB) Recently-Issued Corporate Update - November 20th, 2009
• Soligenix Inc. (SNGX.OB) Taking Steps to Meet Challenges of Vaccine Technology and Biological Warfare - November 20th, 2009